Partnerships

Together, our potential
is limitless.

We are partnering with world leading organisations to ensure the success of our development programs, on our mission to alleviate human suffering.

Camargo Pharmaceuticals

CAMARGO PHARMACEUTICALS
is an integrated strategy, regulatory, and development partner with expertise in the FDA 505(b)2 drug registration pathway. Incannex are collaborating with Camargo Pharmaceuticals on the regulatory strategies across the development programs.

Novotech

NOVOTECH is internationally recognised as a leading regional full-service contract research organization (CRO). Novotech has been engaged to manage the IHL-42X for treatment of obstructive sleep apnoea proof of concept clinical trial.

Labcorp Drug Development

LABCORP DRUG DEVELOPMENT provides extensive experience and services across drug development and diagnostics ranging from preclinical services to post-marketing solutions. Labcorp Drug Development have been engaged as consultants across Incannex’s cannabinoid development programs.

Procaps S.A.

PROCAPS are equipped to provide an end-to-end service that includes formulation development, clinical trial supply and subsequent commercial manufacture. Development at Procaps is supported by its own robust intellectual property portfolio, providing access to a range of proprietary formulation and manufacturing technologies. Procaps have been engaged to develop the formulation of IHL-675A and IHL-42X using their patented Unigel technology.

Vectura

VECTURA is a state-of-the-art contract development and manufacturing organisation (‘CDMO’) that specialises in the development and manufacture of inhaled drugs and their associated delivery products. Vectura have been engaged to develop the IHL-216A formulation.

Avance Clinical

AVANCE CLINICAL is the largest full-service Australian CRO specializing in delivering quality clinical trials, with globally accepted data, in Australia and New Zealand. Avance clinical has been engaged as CRO to manage the IHL-675A phase 1 clinical trial.

BrainPark

BRAINPARK is a world-first neuroscience research clinic dedicated to improving the physical, mental and brain health of Australians. Incannex are collaborating with BrainPark on the clinical development of psychedelics.

Clinical trial sites

The Alfred

THE ALFRED is one of Australia’s top hospitals with proven expertise in clinical trials. Incannex has engaged The Alfred hospital as a trial site for the IHL-42X for treatment of obstructive sleep apnoea proof of concept study.

The Centre for Sleep Science at the University of Western Australia

The CENTRE FOR SLEEP SCIENCE at the University of Western Australia (CSS at UWA) is a world-class facility at the forefront of sleep research and sleep education. CSS at UWA is a trial site for the IHL-42X for treatment of obstructive sleep apnoea proof of concept study.

CMAX Clinical Research

CMAX Clinical Research is an independent clinical research facility based in Adelaide, Australia. CMAX has been established as a Phase I-II unit since December 1993, making it the longest-running in Australia which has consistently maintained world class standards with a commitment to providing excellence and quality in all areas of clinical service. CMAX is the trial site for the IHL-675A Phase 1 study.

Monash University

MONASH is one of the top universities in Australia and are consistently ranked in the world’s top 100 universities. Incannex are collaborating with Monash University on the clinical development of psychedelics.

Contact us today

For all partnership opportunities and development programs enquiries, please contact us.

Subscribe and stay connected

Stay up to date with Incannex’s leading research and development programs, multiple secondary assets, investor relations and biotechnology advancements.

"*" indicates required fields